

A practical guide for providers to help patients find Amoxapine during the ongoing shortage. Includes 5 actionable steps, alternatives, and workflow tips.
When patients call your office saying they can't fill their Amoxapine prescription, it's more than an inconvenience — it's a clinical concern. Abrupt discontinuation of a tricyclic antidepressant can trigger withdrawal symptoms and depressive relapse. As a prescriber, you're in a unique position to help patients navigate the current shortage and maintain treatment continuity.
This guide provides a practical, step-by-step framework for helping your patients access Amoxapine — or transition safely to an alternative when the medication cannot be found.
Amoxapine (formerly branded as Asendin) has been in an active drug shortage since August 2024. Key facts for your practice:
For the full shortage timeline and background, see our provider briefing on the Amoxapine shortage for prescribers.
Understanding the barriers your patients face helps you intervene more effectively:
With only Teva producing Amoxapine, there is no fallback supplier. Any production issue — from raw material delays to quality holds — creates immediate nationwide impact.
Most chain pharmacies stock based on demand. Because Amoxapine is a low-volume medication, many pharmacies don't carry it routinely. During a shortage, even pharmacies that normally stock it may be unable to reorder.
During shortages, wholesalers often allocate limited supply based on each pharmacy's purchasing history. Pharmacies that rarely order Amoxapine may receive little to no allocation, even if they have patients waiting.
Many patients don't know about alternative pharmacy options (independent pharmacies, mail-order, compounding). They may call two or three chain pharmacies, get turned away, and then feel stuck.
Run a report in your EHR or practice management system to identify all patients currently prescribed Amoxapine. Rather than waiting for patients to call with fill problems, reach out proactively to:
Medfinder for Providers is a free tool that searches pharmacy availability in real time. You can:
Include medfinder.com/providers in patient-facing handouts or after-visit summaries.
Maximize your patients' chances of filling their prescriptions by being flexible with your prescribing:
For each Amoxapine patient, document a preferred alternative in the chart. This allows for a faster transition if the medication becomes completely unavailable. Recommended alternatives include:
Note: Amoxapine has unique D2/D4 receptor antagonism. For patients with psychotic depression, pairing a TCA with a low-dose atypical antipsychotic may be necessary to replicate this effect.
For patient-friendly alternative information, direct patients to our guide on alternatives to Amoxapine.
If commercial Amoxapine tablets are unavailable and the patient needs to stay on the medication, compounding is a viable option:
Here is a comparison table of common TCA alternatives to Amoxapine:
Incorporate these into your clinical workflow to stay ahead of the shortage:
The Amoxapine shortage requires provider engagement beyond the prescription pad. By proactively identifying affected patients, leveraging tools like Medfinder for Providers, prescribing flexibly, and maintaining documented transition plans, you can protect your patients from treatment interruptions.
The shortage may continue throughout 2026. Building these practices into your workflow now will save time and improve outcomes for your Amoxapine patients.
For related provider resources, see our briefing on the Amoxapine shortage for prescribers and our guide on how to help patients save money on Amoxapine.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.